{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:03:53Z","timestamp":1792631033630,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Since 2003 when memantine was first approved for use in the management of moderate-severe Alzheimer\u2019s dementia, its use has become more widespread and is being explored in other diseases like neuropathic pain, epilepsy, and mood disorders. Our case uniquely highlights two important adverse effects in a patient who overdosed on memantine. One is hypertension, which is easy to overlook as a medication side effect. The other is echolalia which is the repetition of words and phrases spoken by another person. It is commonly seen in children with autism spectrum disorder and has been reported in older adults with head injuries, delirium, and neurocognitive disorders. The aim of this patient story is to highlight the importance of medication reconciliation with caregivers and knowledge of adverse drug reactions in patient management. This case report has been presented previously in the form of an abstract at the American Geriatrics Society Presidential poster session in May 2023.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>Our patient is an 86-year-old man with mild dementia and hypertension, who was brought to the emergency department (ED) due to abrupt onset of altered mental status and auditory hallucinations. Investigations including blood work, CT head and an electroencephalogram (EEG) did not reveal an etiology for this change in his condition. Due to elevated blood pressure on presentation, a nicardipine drip was started, and he was given IV midazolam to assist with obtaining imaging. While reviewing medications with his daughter, it was noted that sixty memantine pills were missing from the bottle. Poison control was contacted and they confirmed association of these features with memantine. With supportive care, his symptoms resolved in less than 100\u00a0h, consistent with the half-life of memantine. Notably, our patient was started on Memantine one month prior to this presentation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Hypertensive urgency and echolalia were the most striking symptoms of our patient\u2019s presentation. Though hypertension is a known sign of memantine overdose, it can easily be contributed to medication non-compliance in patients with dementia, being treated for hypertension. According to our literature review, this the first case of memantine overdose presenting with echolalia, a sign that is not commonly associated with adverse reactions to medications. This highlights the importance of an early medication review, especially with caregivers of people with dementia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12877-024-04658-2","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T16:02:53Z","timestamp":1706803373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Case report: a unique presentation of memantine overdose causing echolalia and hypertension"],"prefix":"10.1186","volume":"24","author":[{"given":"Sana","family":"Durrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaista","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"4658_CR1","unstructured":"Memantine. - Drug usage statistics, United States, 2013\u20132020. ClinCalc DrugStats Database. Accessed 06\/11\/2023. https:\/\/clincalc.com\/DrugStats\/Drugs\/Memantine."},{"issue":"4","key":"4658_CR2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/yic.0000000000000032","volume":"29","author":"H Taipale","year":"2014","unstructured":"Taipale H, Tanskanen A, Koponen M, Tolppanen AM, Tiihonen J, Hartikainen S. Antidementia drug use among community-dwelling individuals with Alzheimer\u2019s disease in Finland: a nationwide register-based study. Int Clin Psychopharmacol Jul. 2014;29(4):216\u201323. https:\/\/doi.org\/10.1097\/yic.0000000000000032.","journal-title":"Int Clin Psychopharmacol Jul"},{"issue":"1","key":"4658_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40120-016-0057-1","volume":"6","author":"K Kadohara","year":"2017","unstructured":"Kadohara K, Sato I, Doi Y, et al. Prescription patterns of medications for Alzheimer\u2019s Disease in Japan from 2010 to 2015: a descriptive pharmacy claims database study. Neurol Ther Jun. 2017;6(1):25\u201337. https:\/\/doi.org\/10.1007\/s40120-016-0057-1.","journal-title":"Neurol Ther Jun"},{"issue":"4","key":"4658_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40266-017-0446-x","volume":"34","author":"L Calv\u00f3-Perxas","year":"2017","unstructured":"Calv\u00f3-Perxas L, Turr\u00f3-Garriga O, Vilalta-Franch J, et al. Trends in the prescription and long-term utilization of Antidementia drugs among patients with Alzheimer\u2019s Disease in Spain: a Cohort Study using the Registry of dementias of Girona. Drugs Aging Apr. 2017;34(4):303\u201310. https:\/\/doi.org\/10.1007\/s40266-017-0446-x.","journal-title":"Drugs Aging Apr"},{"issue":"1","key":"4658_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","volume":"6","author":"J Johnson","year":"2006","unstructured":"Johnson J, Kotermanski S. Mechanism of action of memantine. Curr Opin Pharmacol. 2006;6(1):61\u20137. https:\/\/doi.org\/10.1016\/j.coph.2005.09.007.","journal-title":"Curr Opin Pharmacol"},{"key":"4658_CR6","unstructured":"Ebixa (Memantine). Product information package leaflet. European Medicines Agency. Accessed 06\/11\/2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ebixa#product-information-section."},{"issue":"3","key":"4658_CR7","doi-asserted-by":"publisher","first-page":"CD003154","DOI":"10.1002\/14651858.CD003154.pub6","volume":"3","author":"R McShane","year":"2019","unstructured":"McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;3(3):CD003154\u20134. https:\/\/doi.org\/10.1002\/14651858.CD003154.pub6.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"4658_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/gps.2384","volume":"25","author":"RW Jones","year":"2010","unstructured":"Jones RW. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatr Psychiatry. 2010;25(6):547\u201353. https:\/\/doi.org\/10.1002\/gps.2384.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"10","key":"4658_CR9","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1586\/ern.11.132","volume":"11","author":"D Lo","year":"2011","unstructured":"Lo D, Grossberg GT. Use of memantine for the treatment of dementia. Expert Rev Neurother 2011\/10\/01. 2011;11(10):1359\u201370. https:\/\/doi.org\/10.1586\/ern.11.132.","journal-title":"Expert Rev Neurother 2011\/10\/01"},{"issue":"3","key":"4658_CR10","first-page":"234","volume":"30","author":"S Lu","year":"2018","unstructured":"Lu S, Nasrallah HA. The use of memantine in neuropsychiatric disorders: an overview. Ann Clin Psychiatry Aug. 2018;30(3):234\u201348.","journal-title":"Ann Clin Psychiatry Aug"},{"issue":"1","key":"4658_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4103\/ijpc.ijpc_189_18","volume":"25","author":"AS Nair","year":"2019","unstructured":"Nair AS, Sahoo RK. Efficacy of Memantine Hydrochloride in Neuropathic Pain. Indian J Palliat Care Jan-Mar. 2019;25(1):161\u20132. https:\/\/doi.org\/10.4103\/ijpc.ijpc_189_18.","journal-title":"Indian J Palliat Care Jan-Mar"},{"issue":"3","key":"4658_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/brain\/awac380","volume":"1","author":"K Schiller","year":"2023","unstructured":"Schiller K, Berrahmoune S, Dassi C, et al. Randomized placebo-controlled crossover trial of memantine in children with epileptic encephalopathy. Brain Mar. 2023;1(3):873\u20139. https:\/\/doi.org\/10.1093\/brain\/awac380.","journal-title":"Brain Mar"},{"key":"4658_CR13","doi-asserted-by":"publisher","unstructured":"Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. The Lancet Neurology. 2007\/09\/01\/ 2007;6(9):782\u2013792. https:\/\/doi.org\/10.1016\/S1474-4422(07)70195-3","DOI":"10.1016\/S1474-4422(07)70195-3"},{"issue":"8","key":"4658_CR14","doi-asserted-by":"publisher","first-page":"Cd013845","DOI":"10.1002\/14651858.CD013845.pub2","volume":"25","author":"A Brignell","year":"2022","unstructured":"Brignell A, Marraffa C, Williams K, May T. Memantine for autism spectrum disorder. Cochrane Database Syst Rev Aug. 2022;25(8):Cd013845. https:\/\/doi.org\/10.1002\/14651858.CD013845.pub2.","journal-title":"Cochrane Database Syst Rev Aug"},{"issue":"9","key":"4658_CR15","first-page":"527","volume":"112","author":"N Cekmen","year":"2011","unstructured":"Cekmen N, Bedel P, Erdemli O. A memantin HCL intoxication responsive to plasmapheresis therapy. Bratisl Lek Listy. 2011;112(9):527\u20139.","journal-title":"Bratisl Lek Listy"},{"issue":"3","key":"4658_CR16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/ggi.12375","volume":"15","author":"U Safer","year":"2015","unstructured":"Safer U, Doruk H, Tasci I. Memantine overdose in a non-demented older adult. Geriatr Gerontol Int. 2015;15(3):383\u20133. https:\/\/doi.org\/10.1111\/ggi.12375.","journal-title":"Geriatr Gerontol Int"},{"key":"4658_CR17","doi-asserted-by":"publisher","unstructured":"Jarvis B, Figgitt DP, Memantine. Drugs Aging. 2003;20. https:\/\/doi.org\/10.2165\/00002512-200320060-00005.","DOI":"10.2165\/00002512-200320060-00005"},{"issue":"10","key":"4658_CR18","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/mds.25103","volume":"27","author":"C Ganos","year":"2012","unstructured":"Ganos C, Ogrzal T, Schnitzler A, M\u00fcnchau A. The pathophysiology of echopraxia\/echolalia: relevance to Gilles De La Tourette syndrome. Mov Disord. 2012;27(10):1222\u20139. https:\/\/doi.org\/10.1002\/mds.25103.","journal-title":"Mov Disord"},{"key":"4658_CR19","doi-asserted-by":"publisher","unstructured":"NIH National Library of Medicine StatPearls: Echolalia. Treasure Island, StatPearls Publishing FL, Taupin D, Racela R, Friedman D. Ifosfamide chemotherapy and nonconvulsive status epilepticus. Clinical EEG and Neuroscience. 2013;45(3):222\u20135. https:\/\/doi.org\/10.1177\/1550059413500777.","DOI":"10.1177\/1550059413500777"},{"issue":"4","key":"4658_CR20","doi-asserted-by":"publisher","first-page":"620","DOI":"10.5799\/ahinjs.01.2014.04.0472","volume":"5","author":"E Ak\u0131l","year":"2014","unstructured":"Ak\u0131l E, Alp R, Atli A, Acar A, \u00d6zdemir HH. A case of echolalia in a topiramate induced patient with epilepsy. J Clin Exp Invest. 2014;5(4):620\u20132. https:\/\/doi.org\/10.5799\/ahinjs.01.2014.04.0472.","journal-title":"J Clin Exp Invest"},{"issue":"2","key":"4658_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.21466\/ac.btstaea.2017","volume":"5","author":"J Yu","year":"2017","unstructured":"Yu J, Ooi E. Baclofen-induced tourette\u2010like syndrome: tics and echolalia. Anaesth Cases. 2017;5(2):27\u20139. https:\/\/doi.org\/10.21466\/ac.btstaea.2017.","journal-title":"Anaesth Cases"},{"key":"4658_CR22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ana.21597","volume":"65","author":"ML Berthier","year":"2009","unstructured":"Berthier ML, Green C, Lara JP, Higueras C, Barbancho MA, D\u00e1vila G, Pulverm\u00fcller F. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. Ann Neurol. 2009;65:577\u201385. https:\/\/doi.org\/10.1002\/ana.21597.","journal-title":"Ann Neurol"},{"issue":"5","key":"4658_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ana.21597","volume":"65","author":"ML Berthier","year":"2009","unstructured":"Berthier ML, Green C, Lara JP, et al. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. Ann Neurol. 2009;65(5):577\u201385. https:\/\/doi.org\/10.1002\/ana.21597.","journal-title":"Ann Neurol"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-024-04658-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-024-04658-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-024-04658-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T16:04:35Z","timestamp":1706803475000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-024-04658-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4658"],"URL":"https:\/\/doi.org\/10.1186\/s12877-024-04658-2","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"12 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for case reports is granted under the Johns Hopkins consent to treat and does not require IRB approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for publication of information in an online open-access publication that could lead to identification was obtained from the patient. A completed consent form is available for viewing.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}